1-[2-(4-羧基-2-氧代吡咯烷-1-基)乙基]-5-氧代吡咯烷-3-羧酸 | 2761-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-[2-(4-羧基-2-氧代吡咯烷-1-基)乙基]-5-氧代吡咯烷-3-羧酸
• 中文别名: 1,1′-亚乙基双(5-氧代-3-吡咯烷甲酸)；1,1'-乙烷-1,2-二基双(5-氧代吡咯烷-3-羧酸)
• 英文名称: 5,5'-dioxo-1,1'-ethane-1,2-diyl-bis-pyrrolidine-3-carboxylic acid
• 英文别名: 1,1'-(ethylene)bis[5-oxopyrrolidine-3-carboxylic] acid；1,2-Bis-(5-oxo-3-carboxy-pyrrolidino)-ethan；Ethylenebis(N-4-carboxy-2-pyrrolidone)；1-[2-(4-carboxy-2-oxopyrrolidin-1-yl)ethyl]-5-oxopyrrolidine-3-carboxylic acid
• CAS: 2761-13-9
• 化学式: C₁₂H₁₆N₂O₆
• mdl: MFCD00003202
• 分子量: 284.269
• InChiKey: OGLQPNPPUWVJFV-UHFFFAOYSA-N

物化性质

• 沸点：
  666.8±55.0 °C(Predicted)
• 密度：
  1.491±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  1-[2-(4-羧基-2-氧代吡咯烷-1-基)乙基]-5-氧代吡咯烷-3-羧酸 、 在 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以90%的产率得到
  参考文献：
  名称：

  Higher order iminodiacetic acid libraries for probing protein–protein interactions

  摘要：

  Full details of the preparation of iminodiacetic acid diamide dimer (2040 compounds), trimer (560 compounds), and tetramer (1596 compounds) libraries by multistep convergent solution-phase synthesis for studying protein-protein interactions are provided. The libraries were assembled in a format providing small 8-10 compound mixtures and the deconvolution of many of the small mixtures to identify screening leads by resynthesis of the individual components have been conducted for 320 of the individual compounds to date. A representative example of the subsequent exploration of the structure-activity relationships for an identified receptor binding antagonist (200 additional individual compounds) and steps taken for potential elaboration to a receptor dimerization agonist are defined with preparation of representative linked dimers (70 compounds). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00128-x
• 作为产物：
  描述：

  衣康酸 、 乙二胺 以 水 为溶剂， 以78%的产率得到1-[2-(4-羧基-2-氧代吡咯烷-1-基)乙基]-5-氧代吡咯烷-3-羧酸
  参考文献：
  名称：

  由衣康酸合成可生物降解和可水降解的聚内酰胺酯

  摘要：

  聚内酰胺酯易于由生物基衣康酸制备，并与聚乳酸进行比较。内酰胺环提高了玻璃化转变温度，主链酯基更容易水解，通过在水中搅拌一年完全降解。

  DOI：

  10.1039/c6gc01081d

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。
• [EN] MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING<br/>[FR] MODULATION MITOCHONDRIALE POUR AMÉLIORER LE SYNDROME MÉTABOLIQUE PENDANT LE VIEILLISSEMENT
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2021034548A1

  公开（公告）日：2021-02-25

  Compounds, compositions and methods are provided for mitochondrial modulation. The subject mitochondrial modulator compounds generally include a head group linked to a charged moiety. In certain cases, the head group is a heterocyclic or a heteroaryl group. Aspects of the subject methods include a method of modulating mitochondria. Aspects of the subject methods include treating a subject having a metabolic syndrome-related disease or a symptom thereof by administering to the subject a therapeutically effective amount of a subject compound. In certain cases, the disease is selected from hyperlipidemia, type 2 diabetes, fatty liver disease, obesity, cardiovascular disease and stroke. In certain cases, the symptom is selected from abdominal obesity, insulin resistance, hyperinsulinemia, high levels of blood fats, increased blood pressure, and elevated serum lipids.

  提供了用于线粒体调节的化合物、组合物和方法。所述线粒体调节剂化合物通常包括与带电基团相连的头基团。在某些情况下，头基团是杂环或杂芳基团。所述方法的方面包括调节线粒体的方法。所述方法的方面包括通过向患有代谢综合征相关疾病或其症状的患者施用所述化合物的治疗有效量来治疗患者。在某些情况下，该疾病选自高脂血症、2型糖尿病、脂肪肝病、肥胖症、心血管疾病和中风。在某些情况下，该症状选自腹部肥胖、胰岛素抵抗、高胰岛素血症、高血脂水平、高血压和血清脂质升高。
• FLUORESCENT PROBES FOR QUANTIFICATION OF DNA DAMAGE AND REPAIR
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20210147932A1

  公开（公告）日：2021-05-20

  Probes, methods and kits for detecting and measuring abasic (AP) sites in a nucleic acid are provided. Aspects of the methods include determining glycosylase enzyme activity. Further provided herein are methods of quantifying AP sites in genomic DNA, and quantifying the amount of DNA damage. The subject probes include a fluorophore linked to an alpha nucleophile that reacts with the AP site of the nucleic acid to produce a highly fluorescent conjugate.

  提供用于检测和测量核酸中脱嘌呤（AP）位点的探针、方法和试剂盒。该方法的一些方面包括确定醇基化酶酶活性。此外，还提供了一种在基因组DNA中定量AP位点和DNA损伤量的方法。所述探针包括与α亲核试剂相连的荧光团，该试剂与核酸的AP位点发生反应，产生高度荧光的共轭物。
• Phosphoprotein affinity resins and methods for making and using the same
  申请人：Tchaga Simeonov Grigoriy

  公开号：US20060079671A1

  公开（公告）日：2006-04-13

  Phosphorylated protein (i.e., phosphoprotein) affinity resins and methods for making and using the same are provided. The subject resins include a substrate bonded to aspartate-based tetradentate ligand/metal ion complexes, where the tetradentate ligand/metal ion complexes have high specificity for phosphorylated amino acids. The subject resins find use in a variety of different applications, including phosphoprotein enrichment applications. Also provided are kits and systems that include the subject resins.

  提供了磷酸化蛋白（即磷蛋白）亲和树脂及其制备和使用方法。所述树脂包括与以天冬氨酸为基础的四齿配体/金属离子复合物结合的基质，其中四齿配体/金属离子复合物对磷酸化氨基酸具有很高的特异性。所述树脂可用于各种不同的应用中，包括磷蛋白富集应用。还提供了包括所述树脂的试剂盒和系统。
• [EN] TARGETED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLÉS
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015184246A1

  公开（公告）日：2015-12-03

  The present invention provides pharmacological compounds including a peptide epoxy ketone protease inhibitor conjugated to a binding moiety that directs the peptide epoxy ketone protease inhibitor to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and a peptide epoxy ketone protease inhibitor. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the peptide epoxy ketone protease inhibitor.

  本发明提供了药理化合物，包括肽环氧酮蛋白酶抑制剂与结合基团偶联，以将肽环氧酮蛋白酶抑制剂定向到感兴趣的生物靶点。同样，本发明提供了包括该化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。该化合物可以描述为蛋白质相互作用结合基团-药物偶联物（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和肽环氧酮蛋白酶抑制剂。例如，在某些用于治疗癌症的实施方式中，SDC-TRAP可以包括将Hsp90抑制剂与细胞毒性剂偶联作为肽环氧酮蛋白酶抑制剂。